Photo of Dhandapany Perundurai

Dhandapany Perundurai

  • INSTRUCTOR Pediatrics
Print ProfilePrint Profile


    Dr. Perundurai earned his MS and PhD degrees from India in 2000 and 2008 respectively. He completed his post-doctoral training at Mount Sinai Hospital and was promoted to Instructor in Pediatrics 2014. Dr. Perundurai is interested in identify novel genes and curative drugs for childhood onset cardiomyopathies using various model organisms. 


  • 2015 - 2018
    American Heart Association Scientist Development Grant

  • 2013 - 2013
    Child Health Research Award, Icahn School of Medicine at Mount Sinai, New York

  • 2011 - 2011
    Best Poster Award, Pediatric Research Day, Mount Sinai School of Medicine, New York

  • 2009 - 2009
    Trainee Travel Award, Eastern Society for Pediatric Research, Philadelphia, PA

  • 2009 - 2009
    Finalist, Fellow’s Basic Research Award, Pediatric Academic Societies Annual Meeting, Baltimore



Dhandapany P, Razzaque A, Muthusami U, Kunnoth S, Edwards J, Riess I, Pardo S, Sheng J, Rani D, Rani B, Govindaraj P, Flex E, Mulero-Navarro S, Yokota T, Furutani M, Nishizawa T, Nakanishi T, Robbins J, Limongelli G, Hajjar R, Lebeche D, Bahl A, Khullar M, Rathinavel A, Sadler K, Tartaglia M, Matsuoka R, Thangaraj K, Gelb B. RAF1 mutations in childhood-onset dilated cardiomyopathy.. Nat Genet 2014 June; 46(6): 635-9.

Rani D, Dhandapany P, Nallari P, Narasimhan C, Thangaraj K. A Novel Arginine to Tryptophan (R144W) Mutation in Troponin T (cTnT) Gene in an Indian Multigenerational Family with Dilated Cardiomyopathy (FDCM).. PLoS One. 2014 July; 9(7): e10145.

Dhandapany P, Fabris F, Tonk R, Illaste A, Karakikes I, Sorourian M, Sheng J, Hajjar R, Tartaglia M, Sobie E, Lebeche D, Gelb B. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. . J Mol Cell Cardiol. 2011; 51(1): 4-15.

Rani D, Dhandapany P, Nallari P, Govindaraj P, Singh L, Thangaraj K. Mitochondrial DNA haplogroup 'R' is associated with Noonan syndrome of south India. . Mitochondrion. 2010 March; 10(2): 166-73.

Dhandapany P, Sadayappan S, Xue Y, Powell G, Rani D, Nallari P, Rai T, Khullar M, Soares P, Bahl A, Tharkan J, Vaideeswar P, Rathinavel A, Narasimhan C, Ayapati D, Ayub Q, Mehdi S, Oppenheimer S, Richards M, Price A, Patterson N, Reich D, Singh L, Tyler-Smith C, Thangaraj K. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia.. Nat Genet 2009; 41: 187-191.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Perundurai did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central